Sarah Hochmann

Dr. Sarah Hochmann is a Research Fellow at the Institute of Experimental and Clinical Cell Therapy, Paracelsus Medical University, with 69 research outputs from 2007-2025 demonstrating sustained productivity. Her work focuses on translating regenerative medicine concepts into clinical applications, particularly through extracellular vesicle research and biomarker discovery. Current projects include establishing skin-based migraine biomarkers and developing mRNA therapeutics for tissue repair.

Her research spans regenerative medicine, cell therapy, and translational applications in cardiovascular disease, inflammatory bowel conditions, and neuroscience. Key investigations include myocardial infarction recovery using cardiac microtissues, hydrogen sulfide's role in gut inflammation, neuropeptide involvement in migraine, and 3D chondrogenesis models for cartilage repair. This interdisciplinary approach integrates molecular biology, pharmacology, and clinical medicine to address unmet therapeutic needs.

Analysis of her 2023-2025 publications reveals concentrated efforts on extracellular vesicle mechanisms and migraine biomarker validation. Her work increasingly employs advanced models like porcine myocardial infarction systems and skin explant cultures, with growing emphasis on diagnostic applications alongside therapeutic development. Collaborative authorship patterns indicate expanding national and international research networks.

Dr. Hochmann has not received major scientific awards as per available information.

She currently serves as Co-PI on the active project 'Establishment of biomarkers for migraine in the skin' (2024-2027), which investigates thermoreceptor activation in migraine pathophysiology. Previously, she contributed to the 'scarRNA' project (2017-2018) developing mRNA-based treatments for atrophic scars. Her consistent publication record suggests ongoing grant support for regenerative medicine research, with potential for student involvement in current migraine biomarker studies.

Research is conducted within the Institute of Experimental and Clinical Cell Therapy's collaborative environment, which provides infrastructure for cell therapy development, tissue engineering, and translational studies. The institute supports interdisciplinary projects spanning basic science to preclinical validation, offering opportunities for researchers interested in regenerative medicine applications for cardiovascular, gastrointestinal, and neurological conditions.